Heart Failure Clinical Trials 

According to the U.S Centers for Disease Control and Prevention, more than 6 million adults have heart failure, also known as congestive heart failure. Heart failure may occur suddenly during an acute cardiac event or heart attack or over time, as a person’s heart becomes weaker. The latter type of heart failure often occurs as a result of chronic diseases such as high blood pressure, cardiomyopathy and diabetes.

Our cardiovascular clinical trials may consist of evaluating novel therapies to treat patients with heart failure as well as observational studies.

The following clinical trials are led by physician scientists who are part of the Krannert Cardiovascular Research Center at the IU School of Medicine. 

DISCOVER STUDY:  Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World (Discover-HCM): United States Prospective Registry Study

Objective: To estimate the incidence rate of new or worsening heart failure (HF) due to systolic dysfunction among patients with symptomatic obstructive HCM during periods of exposure to Camzyos and non-Camzyos therapy. 

PI: Roopa A. Rao, MD

NCT No. NCT05489705

Status: Closed to Accrual 

Leg heat therapy to improve functional performance in Heart Failure with Preserved Ejection Fraction

Objective: The primary objective of this pilot study is to establish evidence to support the validity of HT in improving skeletal muscle function and physical capacity with HFpEF.

PI: Onyedika Ilonze, MD, MPH 

Status: Now Enrolling  

NCT No. NCT06388226

REBIRTH STUDY: Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy for Peripartum Cardiomyopathy.

PI: Roopa A. Rao, MD 

Status: Now Enrolling

ODYSSEY STUDY: A Study of Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Objective: The purpose of this study is to evaluate the safety, tolerability, and efficacy of a 48-week course of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

NCT No. NCT5582395

Status: Closed to Accrual 

PROTECT STUDY: Prospera Test Evaluation in Cardiac Transplant

PI: Roopa A. Rao, MD

Status: Closed to Accrual 

SHORE STUDY: Surveillance HeartCare® Outcomes Registry (SHORE)

Objective: To assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients. 

PI: Roopa A. Rao, MD

Status: Closed to Accrual

Role of Right Ventricular Index Of Myocardial Performance (RIMP) In The Diagnosis of Right Ventricular Dysfunction In Heart Failure Patients; A Sub-sahara African Teaching Hospital Experience
Chigozie Chukwuocha, Chikodili Nebuwa, Ebubechukwu Ezeh, Onyedika Ilonze, Patricia Rodriguez Lozano, Olagoke Ale, Jane Ajuluchukwu. Journal of Cardiac Failure. 2023, Jan., Volume 30, Issue 1

Serial Cardiac Troponin Measurements: A Prediction Tool for Heart Failure Risk in Black Patients?
Onyedika J. Ilonze MD, Jeffrey D. Alexis, MD, Anekwe Onwuanyi, MD, Journal of Cardiac Failure. 2022, Aug. 14.

Subjective and Objective Impact of Angiotensin Receptor-Neprilysin on Systemic Right Ventricle Patients
Ephrem G; McCollum JC; Green-Hess D; Guglin MD; Sawada SG, Rao RA; Heart, Lung & Circulation. 2022, July

Comparison of and Frequency of Mortality, Left Ventricular Assist Device Implantation, Ventricular Arrhythmias, and Heart Transplantation in Patients With Familial Versus Nonfamilial Idiopathic Dilated Cardiomyopathy
Rao RA; Kozaily E; Jawaid O; Sabra M; El-Am EA; Chaaya RGB; Woiewodski L; Elsemesmani H; Ramchandani J; Shah C; Guglin M; Das MK; The American Journal of Cardiology. 2022 Jul 29

Bookmark and visit this page for new listings and check out All IN for Health to view more clinical trial opportunities.